

1 What contraceptive side effects are women told about during counseling? Evidence from PMA Ethiopia
2 2019 cross-sectional survey

3

4 Short Title: Contraceptive counseling on side effects

5

6 Linnea A. Zimmerman¹, Isabella Sarria¹, Munir Kassa², Celia Karp¹, Assefa Seme³, Solomon Shiferaw³

7

8 1. Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School
9 of Public Health, Baltimore MD, USA

10 2. Federal Ministry of Health, Ethiopia, Addis Ababa, Ethiopia

11 3. School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia

12

13 Corresponding author:

14 Linnea A. Zimmerman

15 Johns Hopkins Bloomberg School of Public Health

16 Department of Population, Family and Reproductive Health

17 615 N Wolfe St E4531Batlimore, MD 21231

18 linnea.zimmerman@jhu.edu

19 +1 360 300 7301

20

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Abstract

Background Despite widespread concerns about contraceptive side effects, few studies explore the specific side effects women are told about during contraceptive counseling. This study explored patterns of counseling on specific side effects by user characteristics in Ethiopia.

Methods Data were collected from a nationally representative sample of women between October and December 2019. Analyses were restricted to 2,039 current users of hormonal contraception or the non-hormonal IUD. Descriptive analyses identified the types and number of side effects, across all methods and by the injectable, implant, and pill. Multinomial regression identified factors associated with receipt of counseling on bleeding changes only, non-bleeding changes only, or both, relative to no counseling on side effects, adjusting for method type, source, and socio-economic characteristics.

Results Less than 10% of users were told of at least one bleeding and non-bleeding side effect. Relative to implant users, injectable and other method users were less likely to be told about bleeding changes only (aRRR: 0.65, 95% CI: 0.46-0.93 and aRRR: 0.31, 95% CI: 0.16-0.61, respectively) and users of other methods were less likely to be told about both a bleeding and non-bleeding change (aRRR: 0.43, 95% CI: 0.19-0.93). Users who received their method from a non-public source were less likely to receive counseling on any kind of side effect and nulliparous women were less likely to be told about both kinds of side effects.

Conclusion There is need to improve counseling in the private sector. Research to understand provider barriers to counseling on side effects is needed.

47 **Background**

48

49 The provision of unbiased, scientifically accurate information supports the rights of women to make
50 informed decisions about their reproductive health, including their choice of contraceptive method ^{1,2}.

51 Counseling on potential side effects, particularly for hormonal contraceptive methods and the copper
52 IUD, which can induce a range of documented side effects ³, is a critical component of counseling. Fear
53 of side effects or health concerns is among the most common reasons provided for not using a method,
54 despite wanting to delay or prevent pregnancy ⁴⁻⁶, and the most common reason given for contraceptive
55 discontinuation among women at risk of unintended pregnancy ⁷⁻⁹. Counseling that includes information
56 on potential side effects is effective in increasing the likelihood of method adoption and continuation and
57 in decreasing discontinuation rates ¹⁰⁻¹². Conversely, the provision of inaccurate, incomplete, or biased
58 information can increase dissatisfaction and discontinuation ¹³, and most importantly, is a violation of
59 women's right to accurate information, limiting their reproductive autonomy ^{2,14}.

60

61 Recognizing the importance of informing women about potential side effects, recent measurement efforts
62 have prioritized assessing counseling on side effects. Specifically, items measuring the receipt of this
63 information were included in the Method Information Index (MII), a three-question measure evaluating
64 whether a woman was told about 1) methods other than the method she chose, 2) side effects, and 3) what
65 to do if she experienced side effects ¹⁵. Higher scores on the MII have been shown to be associated with
66 contraceptive behavior; women who reported being informed about all aspects of the MII were 80% less
67 likely to discontinue, while those informed about any one aspect of the MII were 68% less likely to
68 discontinue contraceptive use ¹⁶. Given its ease in measurement and interpretation, in addition to its
69 association with key contraceptive behaviors ¹⁷, the MII has been widely used as a proxy to monitor,
70 evaluate, and improve the quality of contraceptive services ¹⁸⁻²¹.

71

72 Despite the utility of the MII, however, evidence gaps remain related to the content and
73 comprehensiveness of counseling on side effects. Identifying the side effects on which women are
74 counseled has important implications for program design and intervention. Chang and colleagues asked
75 women in Pakistan and Uganda to report specific side effects on which they were counseled and adjusted
76 the MII to reflect whether these side effects were consistent with their chosen method. When adjusted for
77 method-specific consistency, MII estimates were up to 50% lower in Pakistan and 30% lower in Uganda,
78 indicating that women were frequently counseled on side effects that were not associated with their
79 chosen method²², an important programmatic finding. Similarly, while women frequently report
80 contraceptive-induced menstrual bleeding changes as a major concern²³, recent population-based surveys
81 have identified a wide-range of side effects, including some such as headaches and nausea, that are
82 reported as, or more, frequently than bleeding changes among hormonal contraceptive and copper IUD
83 users^{24,25}. Women also frequently report concerns of side effects that are not clinically documented,
84 particularly fears of contraceptive-induced infertility or sub-fecundity^{26–29}, which frequently arises in
85 qualitative research as a primary reason to not use hormonal contraceptive methods^{26,27,30,31}.

86 Understanding the specific side effects on which women are counseled, whether clinically validated or
87 not, is thus critical to design counseling tools and training programs that align with side effects women
88 are likely to experience and/or that are of particular concern, such as infertility.

89

90 Such efforts can be further improved by identifying whether the comprehensiveness of side effect
91 counseling varies across women. Recent evidence suggests that women who use long-acting methods are
92 more likely to receive all components of the MII^{19,20}, indicating that method choice may influence the
93 comprehensiveness of counseling services (or vice versa). Similarly, evidence across 25 countries found
94 that the MII was generally positively associated with wealth and education and was higher in urban
95 relative to rural areas and among women who received services from public, relative to private, providers
96²⁰. Additionally, provider-held concerns about contraceptive-induced infertility and other safety concerns
97 may influence counseling for young, unmarried, and nulliparous women^{32–34}. Evidence thus suggests that

98 women of more privileged backgrounds and those who are older and parous may be more likely to
99 receive comprehensive information on side effects, but this has not been documented.

100
101 The purpose of this study is thus to explore patterns of specific side effects on which hormonal
102 contraceptive or copper IUD users are counseled, using nationally representative cross-sectional data
103 from Ethiopia. Our objectives are first to describe overall levels of counseling on specific side effects and
104 then to explore patterns in receipt of counseling by user characteristics; specifically, we examine whether
105 receipt of counseling on bleeding changes, non-bleeding changes, or receipt of both varies by
106 sociodemographic characteristics, accounting for method type and source.

107

108 **Methods**

109 *Study Setting*

110 Ethiopia is a low-income country in sub-Saharan Africa. Modern contraceptive use has increased
111 significantly, from approximately 8% of married women in 2000³⁵ to 35.8% in 2019³⁶. The method mix
112 is largely dominated by the injectable (55% of modern contraception users), but use of the contraceptive
113 implant has grown in recent years, from 16% of the method mix in 2014 to 32% in 2019³⁶. Despite
114 increases in use, recent evidence from Ejigu and colleagues found that quality of counseling services has
115 declined recently, from 39% of modern contraceptive users receiving all three components of the MII in
116 2015 to 12% in 2019²¹. Concerns regarding side effects are consistently reported as a main contributor to
117 discontinuation³⁷⁻³⁹, and discontinuation rates within one year remain high, exceeding 40%³⁷.

118

119 *Data Source*

120 Data came from the PMA Ethiopia 2019 nationally-representative, cross-sectional household survey of
121 women ages 15-49. PMA Ethiopia is a survey platform implemented in collaboration between Addis
122 Ababa University, the Federal Ministry of Health of Ethiopia, and Johns Hopkins University. Multistage
123 sampling using probability proportional to size within region and urban/rural strata was used to select 265

124 enumeration areas (EAs). Between October and December 2019, all households within each EA were
125 listed and 35 households were randomly selected. All women aged 15-49 who were either usual members
126 of the household or who slept in the household the night before were eligible for the cross-sectional
127 survey. After being informed of study procedures, women provided verbal consent and were interviewed
128 by a previously trained female interviewer. A total of 8,837 women were interviewed. More information
129 about the study and design are available from the study protocol ⁴⁰. PMA Ethiopia received ethical
130 approval from Addis Ababa University, College of Health Sciences (Ref: AAUMF 01–008) and the Johns
131 Hopkins University Bloomberg School of Public Health Institutional Review Board (FWA00000287).
132 Personally identifiable information collected during data collection were available to the data
133 management team and PIs during data collection, however, all identifiable information was deleted from
134 all datasets prior to data being available for analysis.

135

136 *Measures*

137 Our outcome measures explored the specific side effects, number of side effects, and types of side effects
138 on which women were counseled. We identified the specific side effects using the question, “*According to*
139 *the provider, what are the possible side effects or problems related to use of [current method]*”, where
140 “current method” indicates the current method used by the woman. Answer options included known side
141 effects, such as changes to menstrual bleeding, in addition to side effects that are reported by women, but
142 which are not clinically validated, such as impacts on fertility ^{24–26}. Answers were coded based on
143 spontaneous response and were not read aloud. After first exploring the list of all side effects, we evaluate
144 the number of side effects on which women reported being counseled. Finally, we construct a four-category
145 variable exploring whether women were counseled on contraceptive-induced bleeding changes only, non-
146 bleeding changes, both, or neither. Table 1 indicates how side effects were grouped.

147 For regression analyses, described further below, we included socio-demographic characteristics

148 identified from previous literature related to receiving more comprehensive counseling ^{19–21}, specifically

149 age (categorical in five year age groups), parity (categorized as 0, 1-2, 3+ births), highest level of

150 schooling attended (none, primary, secondary and above), residence (urban versus rural), and wealth
151 quintile. Recent evidence has also highlighted critical differences in the MII across regions and by method
152 source in Ethiopia ²¹ and we thus include region (Oromiya, Amhara, Addis, Southern Nations,
153 Nationalities, and Peoples Region (SNNP-R)¹, Tigray², and all other regions) and method source
154 (hospital or health center, health post or HEW, private facilities and pharmacies).

155

156 *Analyses*

157 *Analytic Sample and Analysis*

158 Our analytic sample was restricted to women who slept in the household the night before,
159 completed the female questionnaire, and were current users of a hormonal modern method of
160 contraception (implant, injectable, pill, or emergency contraception) or the copper IUD (n=2,039).
161 Descriptive statistics of frequencies and percentages were used to explore patterns of specific side effects
162 and number of side effects on which women were counseled, among all hormonal contraception and
163 copper IUD users and stratified by the three most-commonly used methods (implant, injectable, pill).
164 Sample size limitations prevented stratification by EC or the copper IUD. We then used unadjusted and
165 adjusted multinomial logistic regression models to explore the relationship between receipt of type of side
166 effect counseling and women's sociodemographic characteristics, using women who received no side
167 effect counseling as the reference. Due to high correlation between age and parity ($\rho=0.70$), and wealth
168 and residence ($\rho=0.73$), we do not include age or wealth in the adjusted regression model. Additionally, as
169 marriage is almost universal in the sample (Appendix Table 1), we did not adjust for marital status. Due
170 to sample size limitations, we combine pill, EC, and copper IUD users into one "other" method type.
171 Analyses accounted for complex survey design through application of weights and adjustment for
172 clustering and were conducted using Stata SE 16.1 ⁴¹.

¹ In 2020, a new region, Sidama, was formed from within SNNP-R. Data were collected prior to the creation of this region.

² In 2020, civil conflict began in Tigray leading to a protracted humanitarian emergency. Data were collected prior to the onset of this conflict and are not likely to represent the current situation.

173

174 **Results**

175 Sociodemographic characteristics of users are shown in Appendix Table 1.

176

177 Table 1 below shows the number of side effects on which women were counseled, across all users and by
178 method. Across all users, almost three in four women report not receiving counseling on any side effects.
179 Among women who do receive counseling, most received counseling on only one side effect. A higher
180 percentage of implant users reported receiving any counseling on side effects (35.2%) and on more than
181 one side effect (20.2%) than injectable (23.9% and 14.5%, respectively) or pill users (17.2% and 8.5%,
182 respectively). Pill users received the least amount of side effect counseling, relative to implant and
183 injectable users.

184

	All users	Implant Users	Injectable Users	Pill Users
	%	%	%	%
0	73.0	64.8	76.1	82.8
1	10.5	12.9	9.5	8.7
2	7.0	8.0	6.6	6.5
3	4.8	8.0	3.5	1.0
4+	4.8	6.2	4.4	1.0

185

186 Table 2 shows the percentage of users who reported being told about each of the side effects, shown
187 among all current hormonal users and by implant, injectable, and pill users. The most common side
188 effects on which women were counseled were related to menstrual bleeding changes. Fewer than ten
189 percent of women reported receiving counseling about any other potential side effects.

Table 2: Percentage of current hormonal contraception or copper IUD users who received counseling on each side-effect				
	All current users	Implant users	Injectable users	Pill users
	%	%	%	%
N	2039	675	1,114	158
Bleeding changes				
Less or No Bleeding	12.7	15.7	12.5	1.7
More Bleeding	10.7	15.3	8.8	4.2
Irregular Bleeding	8.8	12.8	7.2	2.4
Spotting	3.7	5.6	2.7	0.9
General Bleeding (non-specific)	2.6	3.5	2.3	0.9
Non-bleeding changes				
Abdominal Pain	0.9	0.8	1.0	0.6
Gain Weight	3.7	4.6	3.5	1.7
Lose Weight	3.7	4.4	3.7	2.3
Acne	1.4	1.0	1.6	1.8
Headache	5.8	9.6	3.8	4.3
Infection	0.4	0.7	0.3	0.6
Nausea	1.0	1.5	0.6	1.6
Menstrual Cramp	1.0	0.1	1.4	2.4
Lower sex drive	0.3	0.3	0.3	0.0
Vaginal dryness	0.2	0.1	0.2	0.0
Infertility/Sterility	1.0	0.1	1.5	0.8
Delayed Fertility	1.1	0.2	1.7	1.3

Method Lost	0.3	0.7	0.1	0.0
Weakness	2.1	3.4	1.4	0.0

191

192

193 Table 3 below shows the distribution of types of side effects on which women were counseled. About

194 20% of all users were counseled on at least one contraceptive-induced menstrual bleeding side effect and

195 about 15% were counseled on a non-bleeding side effect. A higher percentage of implant users (12.9%)

196 reported being told about at least one bleeding and one non-bleeding side effect, but less than five percent

197 of either injectable or pill users reported receiving counseling on both types of side effects.

198

Table 3: Percentage of women who were told about different kinds of side effects, by method type				
	All users	Implant Users	Injectable Users	Pill Users
	%	%	%	%
No side effect	73.0	64.8	76.1	82.8
Bleeding only	11.7	16.2	10.1	3.5
Non-bleeding only	6.0	6.9	5.2	10.1
Both	9.4	12.9	3.6	3.6

199

200

201

202 Unadjusted results assessing the relationship between method choice, selected sociodemographic and

203 environmental factors, and receipt of type of side effect counseling are shown in Table 4 below. Injectable

204 and “other” method users (pill, EC, and copper IUD) were significantly less likely to be told only about a

205 bleeding change (RRR: 0.53 , 95% CI: 0.37-0.75 and RRR: 0.27, 95% CI: 0.14-0.52, respectively) and

206 significantly less likely to be told about both a bleeding change and a non-bleeding side effect (RRR: 0.62
207 , 95% CI: 0.40-0.94 and RRR: 0.33, 95% CI: 0.16-0.68, respectively). Parous women were significantly
208 more likely to receive counseling on at least one bleeding and non-bleeding side effect than nulliparous
209 women. Women who received their method from a private source were significantly less likely to receive
210 counseling on bleeding changes only or on both bleeding changes and non-bleeding side effects (RRR:
211 0.42 , 95% CI: 0.26-0.69 and RRR: 0.23, 95% CI: 0.12-0.44, respectively) while women who received
212 services from a health post or HEW were significantly less likely to receive counseling on at least one of
213 each type of side effect than women who received services from a hospital or health center (RRR: 0.59 ,
214 95% CI: 0.36-0.98). Region, wealth, and education appeared to be largely unrelated to the type of side
215 effect on which women were counseled, with some exceptions.
216

Table 4: Unadjusted multinomial logistic regression results. PMA Ethiopia 2019 cross-sectional survey										
		CIMBC only			non-CIMBC only			Both		
		RRR	95% CI		RRR	95% CI		RRR	95% CI	
Method (ref: implant)										
	Injectable	0.53	0.37	0.75	0.63	0.38	1.06	0.62	0.40	0.94
	Other	0.27	0.14	0.52	0.82	0.45	1.50	0.33	0.16	0.68
Age (ref: 15-19)										
	20-24	0.75	0.35	1.64	0.80	0.33	1.93	1.79	0.68	4.72
	25-29	1.12	0.58	2.16	1.35	0.59	3.08	2.86	1.11	7.38
	30-34	1.17	0.57	2.43	0.66	0.26	1.67	2.19	0.85	5.64
	35-39	1.04	0.57	1.90	0.93	0.36	2.39	1.68	0.64	4.41
	40-44	0.78	0.32	1.93	1.02	0.38	2.70	2.51	0.82	7.66
	45-49	0.81	0.27	2.47	0.57	0.08	3.97	2.08	0.48	9.01
Parity (ref: 0)										
	1-2	1.84	0.92	3.67	1.10	0.54	2.23	3.05	1.49	6.23
	3+	1.69	0.84	3.42	1.11	0.53	2.33	2.47	1.16	5.24
Education (ref: None)										
	Primary	1.13	0.78	1.64	1.19	0.72	1.98	1.05	0.69	1.58
	Secondary	1.38	0.93	2.05	1.63	0.90	2.95	1.73	1.06	2.83
Residence (ref: rural)										
	Urban	1.09	0.74	1.61	1.53	0.92	2.56	1.03	0.67	1.59
Region (ref: Oromiya)										
	Tigray	0.38	0.23	0.64	0.94	0.47	1.89	0.81	0.47	1.39
	Amhara	0.95	0.56	1.62	1.72	0.83	3.56	1.15	0.65	2.03

	Addis	0.62	0.33	1.16	0.76	0.35	1.68	1.14	0.60	2.16
	SNNP	0.74	0.37	1.48	1.11	0.55	2.24	0.78	0.34	1.77
	Other	0.83	0.51	1.36	2.39	1.22	4.68	1.63	0.76	3.50
Wealth (ref: Lowest)										
	Lower	0.79	0.40	1.55	0.38	0.15	0.98	0.87	0.42	1.80
	Middle	1.29	0.60	2.78	0.53	0.20	1.40	1.22	0.63	2.37
	Higher	1.27	0.67	2.40	0.94	0.42	2.12	0.92	0.40	2.10
	Highest	1.35	0.74	2.44	1.03	0.47	2.24	1.27	0.62	2.61
Source of method (ref: Hospital/Health Center)										
	Health Post/HEW	0.76	0.49	1.17	0.73	0.39	1.37	0.59	0.36	0.98
	Non-public	0.42	0.26	0.69	0.56	0.30	1.02	0.23	0.12	0.44

218

219 Adjusted results are shown in Table 5. Results were largely consistent after adjustment. Injectable and
220 other method users were significantly less likely than implant users to be told only about only a bleeding
221 side effect and other method users were significantly less likely to be told about both a bleeding and non-
222 bleeding side effect. Women of higher parity remained significantly more likely to be told about both a
223 bleeding and non-bleeding side effect. Women with secondary education and higher were more likely to
224 receive counseling on bleeding changes only or on both bleeding-and non-bleeding changes.

225

		CIMBC only			non-CIMBC only			Both		
		RRR	95% CI		RRR	95% CI		RRR	95% CI	
Method (ref: implant)										
	Injectable	0.65	0.46	0.93	0.74	0.42	1.28	0.76	0.50	1.15
	Other	0.31	0.16	0.61	0.81	0.42	1.57	0.43	0.19	0.93
Parity (ref: 0)										
	1-2	1.53	0.74	3.17	1.03	0.51	2.09	2.48	1.17	5.29
	3+	1.70	0.79	3.65	1.36	0.64	2.88	2.53	1.15	5.59
Education (ref: None)										
	Primary	1.17	0.77	1.78	1.32	0.75	2.31	1.18	0.78	1.78
	Secondary	1.62	1.01	2.62	1.72	0.90	3.32	2.47	1.44	4.21
Residence (ref: rural)										
	Urban	0.88	0.54	1.42	0.69	0.37	1.32	1.11	0.61	2.02
Region (ref: Oromiya)										
	Tigray	0.40	0.24	0.69	1.00	0.49	2.03	0.87	0.50	1.52
	Amhara	1.03	0.54	1.99	1.44	0.63	3.28	1.34	0.64	2.82
	Addis	0.60	0.32	1.12	0.75	0.34	1.66	1.10	0.57	2.11
	SNNP	0.67	0.33	1.33	1.00	0.49	2.06	0.68	0.29	1.57
	Other	0.86	0.53	1.37	2.19	1.12	4.28	1.78	0.77	4.10
Source of method (ref: Hospital/Health Center)										
	Health Post/HEW	0.92	0.60	1.40	0.94	0.49	1.81	0.68	0.40	1.13

	Non-public	0.49	0.30	0.82	0.49	0.27	0.90	0.27	0.13	0.55
--	------------	------	------	------	------	------	------	------	------	------

226

227

228 **Discussion**

229 We find that most contraceptive users in Ethiopia do not receive sufficient counseling, as approximately
230 three in four users reported they were either not counseled on any side effects or received counseling on
231 only one side effect. Women were most likely to receive counseling on contraceptive-induced menstrual
232 bleeding changes, if they received any counseling at all, and few women received counseling on any non-
233 bleeding changes. Our findings highlight the ongoing need for improvements in access to high-quality,
234 comprehensive contraceptive services.

235

236 Despite current and recent contraceptive users in Ethiopia experiencing a wide range of side effects ²⁴,
237 fewer than 20% of women reported being counseled on at least two side effects, and the majority of
238 women who received counseling only received counseling on contraceptive-induced menstrual bleeding
239 changes. While concerns about bleeding changes do feature heavily in women's worries related to
240 contraceptive side effects ²³, given the range of potential side effects associated with hormonal
241 contraception and the non-hormonal IUD, this limited counseling does not represent sufficient
242 information exchange between providers and clients. Evidence suggests that women learn about side
243 effects, both clinically validated and not, from a range of sources ^{6,31,42}, but largely trust providers to
244 deliver scientifically sound and accurate information ^{13,43}. If women are already aware of and concerned
245 about potential side effects, receiving counseling from providers on the full range of potential side effects
246 is an important opportunity to address concerns and dispel myths. Incorporation of structured tools such
247 as the NORMAL ⁴⁴ tool or the Balanced Counseling Strategy ⁴⁵ could help address some of these
248 counseling gaps and help women make informed decisions about contraception. The Federal Ministry of
249 Health of Ethiopia recently introduced a strategy to improve counseling through the use of structured

250 counseling tools in public health facilities, but implementation was at the onset at the time of this
251 publication.
252
253 Concerns related to contraceptive-induced fertility impairment may be particularly relevant to address, as
254 these concerns, at least qualitatively, remain a major reason for contraceptive non-use^{26,27}. Approximately
255 1% of users reported that they were counseled about infertility or delayed return to fertility. A significant
256 weakness in our study is that we cannot distinguish whether providers were reinforcing or dispelling these
257 concerns, however, our finding that so few women reported being counseled on this topic reinforces that
258 women are unlikely to have this concern addressed by a provider. Additionally, we found that women
259 who were more educated and those who had a greater number of children were more likely to receive
260 counseling on at least one potential bleeding change and one non-bleeding change related to their
261 contraceptive method. While our study is unable to explain what specific behaviors would influence why
262 nulliparous women would receive less comprehensive counseling, fears related to contraception may be
263 particularly relevant to address among younger and nulliparous women as they tend to have the lowest
264 rates of contraceptive use among women who wish to prevent pregnancy^{46,47}. Provider bias towards
265 specific methods based on patient characteristics, such as marital status and parity, may influence
266 counseling, as has been documented elsewhere^{13,14,34,48}. Additional research among providers is necessary
267 to understand how user characteristics influence providers' counseling practices on side effects.
268
269 Finally, receipt of more comprehensive counseling was influenced by method choice and source of
270 method. On the whole, implant users were the most likely to receive counseling on side effects and pill
271 users were the least likely. While side effect profiles differ by method and thus, counseling should also
272 differ, all hormonal methods have the potential for both bleeding and non-bleeding changes. As the
273 implant requires clinical intervention to stop use, it is potentially positive that implant users received
274 relatively more counseling on side effects, however, all women, regardless of the method they select,
275 should be comprehensively counseled in order to make an informed choice. As with directive counseling

276 based on patient characteristics, differences in counseling by method may be explained by provider
277 concerns about safety or preferences for specific methods ³⁴. This finding further reinforces the need for
278 research with providers to understand how knowledge of and concerns about side effects influence
279 counseling.
280
281 These method-specific differences in counseling experiences may in part be explained by method source.
282 For example, pill users may be more likely to source their method from a range of sources and less likely
283 to rely on trained providers. This relationship between method type and counseling remained, however,
284 even after adjusting for method source. Women who received their methods outside of the public health
285 sector had significantly lower relative risk of receiving counseling on any side effects. The majority of
286 women in Ethiopia access their methods through the public health sector ³⁶, but efforts are underway to
287 expand the private sector in Ethiopia through such projects as the Ethiopia Private Health Sector Project
288 ^{49,50}. Evidence suggests that private facilities are less likely to have trained FP providers or clear
289 guidelines and protocols for FP provision ⁵¹. Thus, expansion of the private sector must be done with
290 quality in mind, ensuring that private providers, particularly drug shop owners and pharmacists, are
291 trained to provide comprehensive counseling.
292
293 Our study is not without limitations. Our survey question about contraceptive side effects did not
294 distinguish what information was provided about each side effect or confirm if scientifically accurate
295 information was shared. Such nuance is likely not possible in a population-based survey and requires
296 alternative data collection strategies, such as observation of counseling sessions. Additionally, we
297 collected information retroactively; recall of specific information is likely to fade over time and introduce
298 bias. If so, we may be underestimating the percentage of women who received more comprehensive
299 counseling. Similarly, we collect information only among current users of contraception. Women who
300 discontinued their method prior to the survey or who received counseling but chose not to adopt a method
301 may have received different counseling than women who continued, which is not reflected in our findings

302 due to data limitations. Finally, data were collected in Tigray in 2019 prior to the onset of widespread
303 civil conflict and are not able to be generalized to the current situation. Despite these limitations, we
304 believe that the use a high-quality, nationally representative data source that incorporated detailed
305 information on side effect counseling provides clear evidence of gaps in counseling that must be
306 addressed to enhance informed decision-making and improve reproductive health outcomes.

307

308 **Conclusions**

309 Women in Ethiopia do not receive sufficient information on side effects during contraceptive counseling,
310 particularly related to side effects outside of menstrual bleeding changes. Private health facilities appear
311 to be of particular concern. Efforts to improve counseling, such as structured counseling tools, should be
312 incorporated into the private sector. Additionally, research with providers is necessary to understand and
313 address biases towards specific methods and counseling messages.

314

315 **Declarations**

316 **Acknowledgements**

317 We thank the PMA Ethiopia team for their dedication in conducting the PMA Ethiopia surveys and the
318 respondents for sharing their time and experiences.

319

320

321

- 322
- 323 1. Bruce J. Fundamental Elements of the Quality of Care: A Simple Framework. *Studies in*
324 *Family Planning*. 1990;21(2):61. doi:10.2307/1966669
- 325 2. Hardee K. Operationalizing Human Rights in Sexual and Reproductive Health and Rights
326 Programming: An Example from a Global Family Planning Partnership. Oxford Research
327 Encyclopedia of Global Public Health. doi:10.1093/acrefore/9780190632366.013.239
- 328 3. Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Kowal D, Policar MS. *Contraceptive*
329 *Technology*. 20th Revised. Ardent Media, Inc; 2015.
- 330 4. Sedgh G, Hussain R. Reasons for Contraceptive Nonuse among Women Having Unmet
331 Need for Contraception in Developing Countries. *Studies in Family Planning*.
332 2014;45(2):151-169. doi:10.1111/j.1728-4465.2014.00382.x
- 333 5. Schrupf LA, Stephens MJ, Nsarko NE, et al. Side effect concerns and their impact on
334 women's uptake of modern family planning methods in rural Ghana: a mixed methods study.
335 *BMC Womens Health*. 2020;20:57. doi:10.1186/s12905-020-0885-0
- 336 6. Diamond-Smith N, Campbell M, Madan S. Misinformation and fear of side-effects of family
337 planning. *Culture, Health & Sexuality*. 2012;14(4):421-433.
338 doi:10.1080/13691058.2012.664659
- 339 7. Ali MM, Cleland JG, Shah IH, World Health Organization. *Causes and Consequences of*
340 *Contraceptive Discontinuation: Evidence from 60 Demographic and Health Surveys*. World
341 Health Organization; 2012. Accessed February 7, 2022.
342 <https://apps.who.int/iris/handle/10665/75429>

- 343 8. Bradley SEK, Schwandt HM, Khan S. *Levels, Trends, and Reasons for Contraceptive*
344 *Discontinuation*. ICF Macro; 200AD. Accessed March 5, 2021.
345 <https://www.dhsprogram.com/pubs/pdf/AS20/AS20.pdf>
- 346 9. Jain A, Reichenbach L, Ehsan I, Rob U. "Side effects affected my daily activities a lot": a
347 qualitative exploration of the impact of contraceptive side effects in Bangladesh. *Open*
348 *Access J Contracept*. 2017;8:45-52. doi:10.2147/OAJC.S140214
- 349 10. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance
350 in Mexican women receiving depot-medroxyprogesterone acetate. *Contraception*.
351 2001;63(3):143-146. doi:10.1016/S0010-7824(01)00181-0
- 352 11. Dehingia N, Dixit A, Averbach S, et al. Family planning counseling and its associations with
353 modern contraceptive use, initiation, and continuation in rural Uttar Pradesh, India. *Reprod*
354 *Health*. 2019;16(1):178. doi:10.1186/s12978-019-0844-0
- 355 12. Huda FA, Chowdhuri S, Sirajuddin MFR. Importance of Appropriate Counselling in
356 Reducing Early Discontinuation of Norplant in a Northern District of Bangladesh. *J Health*
357 *Popul Nutr*. 2014;32(1):142-148.
- 358 13. Yirgu R, Wood SN, Karp C, Tsui A, Moreau C. "You better use the safer one... leave this
359 one": the role of health providers in women's pursuit of their preferred family planning
360 methods. *BMC Women's Health*. 2020;20(1):170. doi:10.1186/s12905-020-01034-1
- 361 14. Senderowicz L, Pearson E, Hackett K, et al. 'I haven't heard much about other methods':
362 quality of care and person-centredness in a programme to promote the postpartum
363 intrauterine device in Tanzania. *BMJ Global Health*. 2021;6(6):e005775. doi:10.1136/bmjgh-
364 2021-005775

- 365 15. Jain A, Townshend J, RamaRao S. *Proposed Metrics to Measure Quality: Overview*.
366 Population Council; 2018. doi:10.31899/rh6.1024
- 367 16. Chakraborty NM, Chang K, Bellows B, et al. Association Between the Quality of
368 Contraceptive Counseling and Method Continuation: Findings From a Prospective Cohort
369 Study in Social Franchise Clinics in Pakistan and Uganda. *Glob Health Sci Pract*.
370 2019;7(1):87-102. doi:10.9745/GHSP-D-18-00407
- 371 17. Tin KN, Maung TM, Win T. Factors that affect the discontinuation of family planning
372 methods in Myanmar: analysis of the 2015–16 Myanmar Demographic and Health Survey.
373 *Contracept Reprod Med*. 2020;5(1):20. doi:10.1186/s40834-020-00126-5
- 374 18. Budiharsana MP, Wahyuningsih W, Heywood P. The use of Method Information Index (MII)
375 to monitor the amount of information given to women users of modern contraceptives in
376 Indonesia: results from an analysis of the 2007, 2012 and 2017 demographic and health
377 surveys. *BMC Women's Health*. 2022;22(1):489. doi:10.1186/s12905-022-02094-1
- 378 19. Bullington BW, Tumlinson K, Karp C, et al. Do users of long-acting reversible contraceptives
379 receive the same counseling content as other modern method users? A cross-sectional,
380 multi-country analysis of women's experiences with the Method Information Index in six sub-
381 Saharan African countries. *Contracept X*. 2022;4:100088. doi:10.1016/j.conx.2022.100088
- 382 20. Jain. Examining Progress and Equity in Information Received by Women Using a Modern
383 Method in 25 Developing Countries. *International Perspectives on Sexual and Reproductive*
384 *Health*. 2016;42(3):131. doi:10.1363/42e1616
- 385 21. Ejigu BA, Seme A, Zimmerman L, Shiferaw S. Trend and determinants of quality of family
386 planning counseling in Ethiopia: Evidence from repeated PMA cross-sectional surveys,
387 (2014–2019). *PLOS ONE*. 2022;17(5):e0267944. doi:10.1371/journal.pone.0267944

- 388 22. Chang KT, Mukanu M, Bellows B, et al. Evaluating Quality of Contraceptive Counseling: An
389 Analysis of the Method Information Index. *Studies in Family Planning*. 2019;50(1):25-42.
390 doi:10.1111/sifp.12081
- 391 23. Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women's
392 responses to contraceptive-induced menstrual bleeding changes. *Reprod Health*.
393 2018;15(1):114. doi:10.1186/s12978-018-0561-0
- 394 24. Zimmerman LA, Sarnak DO, Karp C, et al. Measuring experiences and concerns
395 surrounding contraceptive induced side-effects in a nationally representative sample of
396 contraceptive users: Evidence from PMA Ethiopia. *Contraception: X*. 2022;4:100074.
397 doi:10.1016/j.conx.2022.100074
- 398 25. Zimmerman LA, Sarnak DO, Karp C, et al. Association between experience of specific side-
399 effects and contraceptive switching and discontinuation in Uganda: results from a
400 longitudinal study. *Reproductive Health*. 2021;18(1):239. doi:10.1186/s12978-021-01287-5
- 401 26. Sedlander E, Bingenheimer JB, Thiongo M, et al. "They Destroy the Reproductive System":
402 Exploring the Belief that Modern Contraceptive Use Causes Infertility. *Studies in Family*
403 *Planning*. 2018;49(4):345-365. doi:<https://doi.org/10.1111/sifp.12076>
- 404 27. Sedlander E, Bingenheimer JB, Lahiri S, et al. Does the Belief That Contraceptive Use
405 Causes Infertility Actually Affect Use? Findings from a Social Network Study in Kenya.
406 *Studies in Family Planning*. 2021;52(3):343-359. doi:10.1111/sifp.12157
- 407 28. Sedlander E, Yilma H, Emaway D, Rimal RN. If fear of infertility restricts contraception use,
408 what do we know about this fear? An examination in rural Ethiopia. *Reproductive Health*.
409 2022;19(1):57. doi:10.1186/s12978-021-01267-9

- 410 29. Boivin J, Carrier J, Zulu JM, Edwards D. A rapid scoping review of fear of infertility in Africa.
411 *Reproductive Health*. 2020;17(1):142. doi:10.1186/s12978-020-00973-0
- 412 30. Adofo E, Dun-Dery EJ, Kotoh AM, Dun-Dery F, Avoka JA, Ashinyo ME. Fear of infertility
413 limits contraceptive usage among first-time mothers in Ghana: A cross-sectional study.
414 *SAGE Open Medicine*. 2021;9:20503121211021256. doi:10.1177/20503121211021256
- 415 31. Schwarz J, Dumbaugh M, Bapolisi W, et al. “So that’s why I’m scared of these methods”:
416 Locating contraceptive side effects in embodied life circumstances in Burundi and eastern
417 Democratic Republic of the Congo. *Soc Sci Med*. 2019;220:264-272.
418 doi:10.1016/j.socscimed.2018.09.030
- 419 32. Nalwadda G, Mirembe F, Tumwesigye NM, Byamugisha J, Faxelid E. Constraints and
420 prospects for contraceptive service provision to young people in Uganda: providers’
421 perspectives. *BMC Health Serv Res*. 2011;11(1):220. doi:10.1186/1472-6963-11-220
- 422 33. Paul M, Näsström SB, Klingberg-Allvin M, Kiggundu C, Larsson EC. Healthcare providers
423 balancing norms and practice: challenges and opportunities in providing contraceptive
424 counselling to young people in Uganda – a qualitative study. *Global Health Action*.
425 2016;9(1):30283. doi:10.3402/gha.v9.30283
- 426 34. Solo J, Festin M. Provider Bias in Family Planning Services: A Review of Its Meaning and
427 Manifestations. *Glob Health Sci Pract*. 2019;7(3):371-385. doi:10.9745/GHSP-D-19-00130
- 428 35. Central Statistical Agency (CSA), ORC Macro. *Ethiopia Demographic and Health Survey*
429 *2000*. Central Stastical Authority and ORC Macro; 2001. Accessed February 10, 2021.
430 <https://dhsprogram.com/pubs/pdf/FR328/FR328.pdf>

- 431 36. PMA Ethiopia. *PMA Ethiopia: Results from the 2019 Surveys*. Addis Ababa University,
432 School of Public Health and Johns Hopkins Bloomberg School of Public Health; 2020.
433 Accessed January 13, 2023.
434 https://www.pmadata.org/sites/default/files/data_product_results/Ethiopia_2019_Survey_Results_Brief.pdf
435
- 436 37. Tsui AO, Brown W, Li Q. Contraceptive Practice in Sub-Saharan Africa. *Popul Dev Rev*.
437 2017;43(Suppl Suppl 1):166-191. doi:10.1111/padr.12051
- 438 38. Alvergne A, Stevens R, Gurm E. Side effects and the need for secrecy: characterising
439 discontinuation of modern contraception and its causes in Ethiopia using mixed methods.
440 *Contracept Reprod Med*. 2017;2(1):24. doi:10.1186/s40834-017-0052-7
- 441 39. Abebe M, Mersha A, Degefa N, Gebremeskel F, Kefelew E, Molla W. Determinants of
442 induced abortion among women received maternal health care services in public hospitals
443 of Arba Minch and Wolayita Sodo town, southern Ethiopia: unmatched case–control study.
444 *BMC Women’s Health*. 2022;22(1):107. doi:10.1186/s12905-022-01695-0
- 445 40. Zimmerman L, Desta S, Yihdego M, et al. Protocol for PMA-Ethiopia: A new data source for
446 cross-sectional and longitudinal data of reproductive, maternal, and newborn health. *Gates*
447 *Open Res*. 2020;4. doi:10.12688/gatesopenres.13161.1
- 448 41. StataCorp. Stata Statistical Software: Release 16. Published online 2019.
- 449 42. Chebet JJ, McMahon SA, Greenspan JA, et al. “Every method seems to have its problems”-
450 Perspectives on side effects of hormonal contraceptives in Morogoro Region, Tanzania.
451 *BMC Women’s Health*. 2015;15(1):97. doi:10.1186/s12905-015-0255-5

- 452 43. Keesara SR, Juma PA, Harper CC. Why do women choose private over public facilities for
453 family planning services? A qualitative study of post-partum women in an informal urban
454 settlement in Kenya. *BMC Health Serv Res.* 2015;15(1):335. doi:10.1186/s12913-015-0997-
455 7
- 456 44. Rademacher KH, Sergison J, Glish L, et al. Menstrual Bleeding Changes Are NORMAL:
457 Proposed Counseling Tool to Address Common Reasons for Non-Use and Discontinuation
458 of Contraception. *Glob Health Sci Pract.* 2018;6(3):603-610. doi:10.9745/GHSP-D-18-00093
- 459 45. Population Council. *The Balanced Counseling Strategy Plus: A Toolkit for Family Planning*
460 *Service Providers Working in High HIV/STI Prevalence Settings.* Population Council; 2015.
- 461 46. de Vargas Nunes Coll C, Ewerling F, Hellwig F, de Barros AJD. Contraception in
462 adolescence: the influence of parity and marital status on contraceptive use in 73 low-and
463 middle-income countries. *Reproductive Health.* 2019;16(1):21. doi:10.1186/s12978-019-
464 0686-9
- 465 47. Behrman JA, Wright KQ, Grant MJ, Soler-Hampejsek E. Trends in Modern Contraceptive
466 Use among Young Adult Women in sub-Saharan Africa 1990 to 2014. *Studies in Family*
467 *Planning.* 2018;49(4):319-344. doi:10.1111/sifp.12075
- 468 48. Daniele MAS, Cleland J, Benova L, Ali M. Provider and lay perspectives on intra-uterine
469 contraception: a global review. *Reproductive Health.* 2017;14(1):119. doi:10.1186/s12978-
470 017-0380-8
- 471 49. Ministry of Health - Ethiopia, Global Financing Facility, World Bank Group. *Ethiopia Health*
472 *Private Sector Assessment.*; 2019. Accessed October 25, 2022.
473 [https://www.globalfinancingfacility.org/sites/gff_new/files/documents/Ethiopia-health-private-](https://www.globalfinancingfacility.org/sites/gff_new/files/documents/Ethiopia-health-private-sector-assessment.pdf)
474 [sector-assessment.pdf](https://www.globalfinancingfacility.org/sites/gff_new/files/documents/Ethiopia-health-private-sector-assessment.pdf)

- 475 50. The Ethiopia Private Health Sector Project | Abt Associates. Accessed March 21, 2023.
476 <https://www.abtassociates.com/projects/the-ethiopia-private-health-sector-project>
- 477 51. Tessema GA, Mahmood MA, Gomersall JS, et al. Structural Quality of Services and Use of
478 Family Planning Services in Primary Health Care Facilities in Ethiopia. How Do Public and
479 Private Facilities Compare? *International Journal of Environmental Research and Public*
480 *Health*. 2020;17(12):4201. doi:10.3390/ijerph17124201
- 481
482

Appendix Table 1: Sample characteristics of users of hormonal contraception and the IUD; PMA Ethiopia Cross-section 2019			
		Total	
		n (unweighted)	% (weighted)
Method			
	Implant	675	33.2
	Injectable	1114	57.4
	Pill	158	6.5
	Other	73	2.9
Source of Method			
	Hospital/health center	1103	53.4
	Health post/HEW	464	27.0
	Non-public	472	19.6
Age			
	15-19	160	9.0
	20-24	439	21.4
	25-29	578	27.4
	30-34	372	16.8
	35-39	288	14.3
	40-44	160	9.1
	45-49	42	2.2
Marital Status			

	Married	202	8.4
	Unmarried	1837	91.6
Parity			
	0	238	10.8
	1-2	945	44.2
	3+	855	45.0
Education			
	None	648	36.4
	Primary	790	39.6
	Secondary +	601	23.9
Residence			
	Rural	1100	64.1
	Urban	939	35.9
Region			
	Oromiya	449	38.8
	Amhara	451	27.7
	Addis	206	6.4
	SNNP	407	19.4
	Tigray	243	5.2
	Other	283	2.5
Wealth			
	Lowest	241	15.0
	Lower	305	18.3
	Middle	360	21.3
	Higher	421	19.9

483

	Highest	712	25.5
--	---------	-----	------